Lava Therapeutics announced a poster presentation highlighting updated data, including safety, pharmacodynamics and pharmacokinetics from the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsing/refractory chronic lymphocytic leukemia and multiple myeloma at the 64th American Society of Hematology Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10-13, 2022. The presentation included initial data from patients receiving LAVA-051 subcutaneously, along with updates on the intravenous dosing-cohorts. In addition to the favorable safety profile demonstrated as of the data cutoff, LAVA-051 showed predictable and linear pharmacokinetics and on-mechanism pharmacodynamic parameters consistent with Vgamma9Vdelta2-T cell engagement, including increasing occupancy of patient Vgamma9Vdelta2-T cells with LAVA-051 and consistent increases in the expression of T-cell activation markers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LVTX:
- LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
- LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
- LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
- LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer